Checkpoint Therapeutics, Inc.

Overview

• IndustryPharmaceutical Preparations²
• HeadquartersNew York, United States²
• Incorporated inDE⁴
• Business address95 Sawyer Road, Suite 110, Waltham, Ma 02453⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴
• Legal formCorporation²
• LEI549300NTOG3NRUKVKI74²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O The Prentice-Hall Corporation System, Inc., 19808 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 2391515²

See how the biggest companies compare on our leaderboards

We are a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. On December 13, 2024, we announced that the U.S. Food and Drug Administration (“FDA”) granted approval of cosibelimab-ipdl, now referred to as UNLOXCYT™, for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“CSCC”) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. The approval was granted for this indication based upon data from an ongoing multi-regional, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic CSCC.⁵ From its latest annual report

Corporate structure

Checkpoint Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Checkpoint Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Properties, in its own words

Our corporate and executive office is located at 95 Sawyer Road, Suite 110, Waltham, MA, 02453. We are not currently under a lease agreement at 95 Sawyer Road. We believe that our existing facilities are adequate to meet our current requirements. We do not own any real property.

Item 2 of the 10-K filed Mar 28, 2025.⁵

Leadership

Who has led Checkpoint Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• ChairMichael S. Weiss Oct 4, 2016 to Oct 4, 2016¹⁷
• Chief financial officerDavid J. Horin Oct 4, 2016 to Oct 4, 2016¹⁸

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerGarrett F. Gray named Mar 3, 2023 to Jul 10, 2024²⁶
• Executive Officer, DirectorJames F. Oliviero, III named Mar 3, 2023 to Jul 10, 2024²⁶
• DirectorAmit A. Sharma named Jul 10, 2024²⁶

Timeline

1. May 30, 20258-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer²⁷
2. May 29, 20258-K Shareholder vote²⁸
3. May 22, 20258-K Other events²⁹
4. May 13, 20258-K Results of operations³⁰
5. Apr 15, 20258-K Entered a material agreement³¹
6. Mar 28, 20258-K Results of operations³²
7. Mar 10, 20258-K Entered a material agreement; Bylaws or fiscal year changed; Other events³³
8. Jan 10, 20258-K Executive or director change³⁴
9. Dec 16, 20248-K Other events³⁵
10. Nov 12, 20248-K Results of operations³⁶
11. Aug 12, 20248-K Results of operations³⁷
12. Jul 25, 20248-K Other events³⁸

Calendar

When it reported results

1. May 13, 2025Reported quarterly or annual results³⁰
2. Mar 28, 2025Reported quarterly or annual results³²
3. Nov 12, 2024Reported quarterly or annual results³⁶
4. Aug 12, 2024Reported quarterly or annual results³⁷
5. May 10, 2024Reported quarterly or annual results³⁹
6. Mar 22, 2024Reported quarterly or annual results⁴⁰
7. Nov 13, 2023Reported quarterly or annual results⁴¹
8. Aug 14, 2023Reported quarterly or annual results⁴²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

218 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 48 major events, 76 insider forms, 9 large holders, 4 private raises, 66 other. The latest 20:

1. Aug 14, 2025SCHEDULE 13G/A EDGAR
2. Jun 9, 202515-12G EDGAR
3. Jun 4, 2025EFFECT EDGAR
4. Jun 4, 2025EFFECT EDGAR
5. Jun 4, 2025EFFECT EDGAR
6. Jun 4, 2025EFFECT EDGAR
7. Jun 4, 2025EFFECT EDGAR
8. Jun 4, 2025EFFECT EDGAR
9. Jun 3, 20254 EDGAR
10. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
11. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
12. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
13. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
14. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
15. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
16. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
17. May 30, 20254 OWNERSHIP DOCUMENT EDGAR
18. May 30, 2025S-8 POS EDGAR
19. May 30, 2025S-8 POS EDGAR
20. May 30, 2025S-8 POS EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 0 buys and 32 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Beryl Capital Management LLCSCHEDULE 13G/A, 2 filings Mar 17, 2025 to Aug 14, 2025⁴³
• ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 5 filings Feb 14, 2023 to May 15, 2025⁴⁴
• GLAZER CAPITAL, LLCSCHEDULE 13G/A, 2 filings Mar 17, 2025 to May 15, 2025⁴⁵

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jul 2, 2024Filed a private offering of equity Form D: 1 investor so far Form D
2. Jan 27, 2024Filed a private offering of equity Form D: 1 investor so far Form D
3. Mar 30, 2023Filed a private offering of securities Form D: 9 investors so far Form D
4. Feb 22, 2023Filed a private offering of securities Form D: 1 investor so far Form D

SEC filer profile

How Checkpoint Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCheckpoint Therapeutics, Inc.¹
• CIK0001651407
• Employer ID (EIN)47-2568632⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address95 Sawyer Road, Suite 110, Waltham, MA 02453¹
• Phone781-652-4500¹
• Shares outstanding700,000 Common Class A shares; 83,063,733 Common Stock shares as of Mar 25, 2025⁵
• Public float$69.3M as of Jun 30, 2024⁵
• AuditorKPMG, LLP, Boston, MA PCAOB ID 185; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceSep 8, 2015¹
• Filings420 in all: 4 (117), 8-K (88), 10-Q (26), CORRESP (17), 424B5 (14), EFFECT (14), 3 (12), UPLOAD (12)¹
  All 40 form types

  DEFA14A (10), 10-K (9), DEF 14A (8), S-3 (8), SC 13D/A (8), POS AM (6), S-8 (6), S-8 POS (6), SC 13G/A (6), D (5), PRE 14A (5), SC 13G (5), 10-12G/A (4), CT ORDER (4), RW (4), SCHEDULE 13G/A (4), 10-12G (3), SCHEDULE 13D/A (3), 5 (2), SCHEDULE 13G (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 8-A12B (1), CERTNAS (1), DEF 14C (1), DEFM14A (1), FWP (1), PRE 14C (1), PREM14A (1), S-1 (1), SC 13D (1)

• Latest filingsAnnual report (10-K) Mar 28, 2025
  Quarterly report (10-Q) May 13, 2025
  Proxy statement (DEF 14A) Apr 2, 2024
  Latest 8-K (8-K) May 30, 2025

Securities registered for trading

From the cover page of the 10-K filed Mar 28, 2025 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks Checkpoint Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 28, 2025: 62 risks under these headings, as written.⁵

• Risks Related in Drug Development, and the Commercialization of our FDA Approved Drug UNLOXCYT (cosibelimab-ipdl)
• Because results of preclinical studies and early clinical trials are not necessarily predictive of future results, any product candidate we advance may not have favorable results in later clinical trials or receive regulatory approval. Moreover, interim, “top-line,” and preliminary data from our clinical trials that we announce or publish may change, or the perceived product profile may be negatively impacted, as more patient data or additional endpoints (including efficacy and safety) are analyzed.
• Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.
• Difficulties in the enrollment of patients in clinical trials may prevent or delay receipt of necessary regulatory approvals.
• We may not receive regulatory approval for our product candidates, or their approval may be delayed, which would have a material adverse effect on our business and financial condition.
• If serious adverse or unacceptable side effects are identified during the development of one or more of our product candidates or any future product candidate, we may need to abandon or limit our development of some of our product candidates.
• Public concern regarding the safety of drug products could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs.
• Even if one or more of our product candidates receives regulatory approval, such as UNLOXCYT, it and any other products we may market will remain subject to substantial regulatory scrutiny. If we are unable to maintain current approvals of UNLOXCYT, our business will be materially harmed.
• Approval of UNLOXCYT or any of our product candidates in the United States does not assure approval of UNLOXCYT in foreign jurisdictions.
• Regulatory approval by the FDA, or any similar regulatory authorities outside the United States, is limited to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.
• We will need to obtain FDA approval of any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business.
• If our competitors develop treatments for any of our product candidates’ target indications and those competitor products are approved more quickly, marketed more successfully or demonstrated to be more effective, the commercial opportunity for UNLOXCYT, our product candidates, will be reduced or eliminated.

Legal proceedings

We and James Oliviero have been named as defendants in a consolidated putative stockholder class action lawsuit pending in the United States District Court for the Southern District of New York (the “Court”), which was filed on April 5, 2024. The action is styled In re Checkpoint Therapeutics, Inc. Securities Litigation, No. 1:24-cv-02613-PAE (the “Securities Class Action”). On June 21, 2024, the Court appointed a lead plaintiff for the putative class and approved his choice of lead counsel. The lead plaintiff filed his amended complaint (the “Amended Complaint”) on August 23, 2024, which alleges that defendants violated the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and SEC Rule 10b-5 promulgated thereunder by making false and misleading statements and omissions, and that James Oliviero is named as a control person under Section 20(a) of the Exchange Act. The Amended Complaint was filed on behalf of stockholders who purchased shares of our common stock between March 10, 2021 and December 15, 2023, and seeks, among other things, monetary damages on behalf of the purported class. Defendants moved to dismiss the Amended Complaint on October 23, 2024, and the motion was fully briefed in February 2025.

The opening of Item 3, Legal Proceedings.⁵